Fig. 3: αCD45–cytokine therapy eradicates treated tumors and elicits robust systemic responses.
From: Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity
a, Overall survival of C57BL/6J mice (MC38: n = 5 per group; B16F10: n = 10 in untreated cohort, n = 10 in IgG-Cyt cohort, n = 19 in αCD45-Cyt cohort across two to five independent experiments) inoculated with 106 tumor cells and treated with 1 µg of αCD45-IL-12 and 10 µg of αCD45-IL-15 (referred to as αCD45-Cyt) or treated with 1 µg of IgG-IL-12 and 10 µg of IgG-IL-15 (referred to as IgG-Cyt) as shown on the experimental timelines. d, day. Statistical comparison calculated by log(rank) (Mantel–Cox) test shown between IgG-Cyt and αCD45-Cyt groups. b, Overall survival of C57BL/6J mice (n = 5/group) bearing B16F10 tumors treated with αCD45-Cyt therapy in combination with depleting antibodies or performed in knockout mice as shown. c, Overall survival of C57BL/6J mice cured of B16F10 tumors rechallenged with 105 B16F10 cells 100 d after the initial challenge. d, C57BL/6J mice bearing MC38 tumors on both flanks treated with 1 µg of IL-12 and 10 µg of IL-15 in the right tumor only at the indicated times (n = 10 mice in untreated cohort, n = 10 in IgG-Cyt cohort, n = 9 in αCD45-Cyt cohort across two independent experiments). Individual tumor growth curves from one representative experiment are shown. e, Overall survival from experiment shown in d. f, C57BL/6J mice bearing bilateral MC38 tumors (n = 5 mice in all treatment groups) treated with αCD45-Cyt therapy in the presence of FTY720 starting on day 5. The mean tumor growth curve ± s.d. is shown. g, Overall survival from experiment shown in f. h, Overall survival of C57BL/6J mice bearing contralateral B16F10 tumors treated with 1 µg of IL-12 and 10 µg of IL-15 as shown (n = 5 mice per group). P values were determined by log(rank) (Mantel–Cox) test from stated replicates. Exact P values are denoted in the figure. For all the plots, the arrows indicate treatment.
